Genital Atrophy on Testosterone Raises Care Gaps for Transmasculine Patients
Genital atrophy remains a clinically important but often under-discussed consequence of testosterone therapy in transmasculine individuals. The study framed the problem around three tightly linked issues: what symptoms patients experience, which treatments they prefer, and what keeps them from getting care. In practice, those three questions determine whether a problem stays manageable or becomes a source of ongoing pain, bleeding, dryness, and avoidance of sexual or gynecologic care.
For many patients, testosterone is central to gender-affirming treatment. It can also shift the genital and vaginal tissue environment in ways that resemble hypoestrogenic atrophy, with thinning mucosa, reduced lubrication, tissue fragility, and discomfort. Those changes can affect daily comfort as well as intimacy, pelvic examinations, and self-image. A study focused on symptom experiences and treatment preferences is clinically relevant because the problem is not simply anatomical; it can influence whether patients remain engaged with care at all.
The title alone signals a patient-centered approach rather than a narrow endocrine measurement. Instead of asking only what happens to tissue, the investigators centered the lived experience of genital atrophy in transmasculine individuals using testosterone. That matters because the same symptom can be interpreted very differently depending on whether it is discussed as a side effect, a dysphoria trigger, a sexual health issue, or a gynecologic concern. Each framing changes the likelihood that a patient will bring it up and the likelihood that a clinician will respond in a useful way.
Why Testosterone-Associated Atrophic Symptoms Are Easy to Miss
Atrophic genital symptoms can sit at the intersection of endocrinology, sexual medicine, and gender-affirming care. They may be mistaken for infection, dismissed as an expected consequence of testosterone, or left unaddressed because the visit is focused on other transition-related goals. When symptoms are normalized without being treated, patients may adapt by avoiding penetrative sex, skipping pelvic care, or tolerating chronic irritation and bleeding.
The biological rationale is straightforward. Testosterone suppresses ovarian function in many patients, lowers endogenous estrogen exposure, and can contribute to a less estrogenized tissue state. In the vaginal and vulvar region, that can mean dryness, burning, dyspareunia, and increased susceptibility to microtrauma. A patient may not describe the issue as “atrophy” at all. They may report pain, tearing, spotting, dryness, or a sense that something has changed since starting hormones. Clinical labeling matters less than recognition.
One sentence captures the bedside consequence plainly: untreated genital atrophy can quietly erode access to care.
Symptom Experience Drives Treatment Acceptability
The study’s focus on symptom experiences suggests a broader clinical problem: treatments can only work if patients can tolerate them, understand them, and trust that they fit within gender-affirming goals. In transmasculine care, even standard gynecologic therapies may carry psychological or practical barriers. Some patients may worry that a local hormonal treatment will undermine masculinization, while others may dislike vaginal administration because of dysphoria or prior trauma. Others may simply not know that treatment options exist.
Because the article centers treatment preferences, the relevant clinical question is not whether one therapy is theoretically effective, but which interventions patients are willing to consider. In this setting, the preferred option may depend on the route of administration, the degree of systemic hormone exposure, the perceived impact on masculinization, and whether the therapy can be used discreetly. A patient who is open to symptom relief may still reject a treatment if it is framed in a way that conflicts with their gender goals.
The same is true of the care setting itself. A patient may accept help from a clinician who understands transgender health and uses precise, affirming language, yet decline care in a setting where the conversation feels pathologizing. Preferences are not secondary details; they shape whether treatment is started, continued, or abandoned.
Barriers to Care Are Often Structural Before They Are Medical
The title also places barriers to care alongside symptoms and preferences, which is an important signal. In gender-affirming medicine, barriers are often layered: inadequate clinician training, limited access to experienced providers, concern about being misunderstood, fear of stigmatizing questioning, and uncertainty about which specialty should manage the problem. Some patients encounter a practical gap as well — they may not have a regular clinician comfortable addressing genital symptoms in the context of testosterone use.
Barrier analysis is especially important because symptoms that could be managed conservatively may become persistent when care is delayed. A patient with dryness or irritation may try self-management for months before asking for help. If prior encounters were dismissive or intrusive, that delay can extend even further. Once care is sought, a patient may still face a narrow menu of options if the clinician is unfamiliar with transgender-specific sexual health needs.
This is where a focused study can influence practice even before all outcome data are known. Simply asking transmasculine individuals how they experience symptoms and what prevents them from seeking treatment can expose points where current systems fail. Those failures may be clinical, but they are also communicational and institutional.
What Clinicians Can Do While Evidence Accrues
Even without detailed results in the title-level record, the study points to a practical bedside message: clinicians should ask directly about genital comfort, bleeding, dryness, pain with sex, and discomfort during examinations in transmasculine patients receiving testosterone. Waiting for spontaneous disclosure will miss many cases. A neutral, matter-of-fact question often does more than a long explanation.
The next step is matching management to the patient’s goals. Some patients may want symptom relief with the least possible interference in their current hormone regimen. Others may care more about avoiding any intervention that feels incompatible with their transition. A productive discussion should include the route of therapy, possible local effects, and how the patient prefers to frame the problem. In gender-affirming care, trust often determines whether a plan is acceptable long before efficacy becomes relevant.
This abstract also serves as a reminder that sexual health and transition-related care should not be separated artificially. When testosterone therapy produces genital symptoms, those symptoms deserve the same seriousness given to any other chronic medication effect. The unresolved issue is not whether the discomfort is real; it is how often it is recognized early enough for treatment to be useful. Future full-text data will be needed to show which symptoms were most common, which therapies patients preferred, and which barriers were most consequential in this cohort.